The latest escalation in the trade war ups the odds the economy will fall into recession and that the Fed will aggressively cut rates.Market Insiderread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
"We don't need China and, frankly, would be far better off without them," Trump tweeted.Politicsread more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
"My only question is, who is our bigger enemy, Jay Powell or Chairman Xi?" Trump wrote amid a series of tweets that rattled markets Friday.Politicsread more
Supreme Court Justice Ruth Bader Ginsburg has completed a three-week course of radiation therapy for cancer, the top court said in a statement Friday.Politicsread more
Oil prices fell on Friday after China unveiled retaliatory tariffs against about $75 billion worth of U.S. goods, marking another escalation of a protracted trade dispute...Energy Commoditiesread more
The president tweeted Friday morning that he was ordering "our great American companies" to "immediately start looking for an alternative to China."Marketsread more
Yields slipped after Powell said the central bank will continue to act as appropriate to sustain the economic expansion.Bondsread more
Multinationals that rely on the supply chain from China are tumbling after President Donald Trump ordered them to find alternatives to their Chinese operations.Marketsread more
Semiconductor stocks and shares of Apple slid on Friday after President Donald Trump said U.S. companies should "immediately start looking for an alternative" to their...Technologyread more
Three weeks into 2018, deal activity in the biotech sector is already almost halfway to what it was in 2017, at least in terms of size.
In the early hours of Monday morning, French drug giant Sanofi said it would buy hemophilia drugmaker Bioverativ, a Biogen spinout that is less than a year old, for $11.6 billion. Hours later, cancer drugmaker Celgene announced a deal for its partner, Juno Therapeutics, for $9 billion.
A pickup in M&A activity is always a bull thesis for biotech investors, especially after what Jefferies analyst Michael Yee called "a relatively lackluster year for biopharma M&A" in 2017.
There were only 12 public deals last year, for a total value of $50 billion, Yee wrote in a research note last week — and a large portion of that was made up of J&J's $30 billion purchase of Swiss biotech Actelion.
Will deals, as biotech investors perennially hope, beget more deals? Biotech investors seem to think so, boosting the IBB biotech ETF by more than 2 percent Monday, and the XBI (in which both Bioverativ and Juno are among the heaviest-weighted stocks) by 3.5 percent. Cue the matchmaking.
Gilead, Amgen, Pfizer, Merck and Johnson & Johnson top out the list of biggest cash holders, according to Baird Research. The list breaks out overseas holdings versus cash in the U.S. — seen as important in light of the tax overhaul giving U.S. companies cheaper access to their overseas cash piles.
Though Gilead acquired Kite Pharma last year for $11.9 billion in the year's other major biotech deal, it's still got $41 billion, Baird points out, as does Amgen. Pfizer's cash, by Baird's tally, is $24 billion, though the pharma giant has signaled it has much greater spending power than that.
As for targets? Today's deals fall neatly into the pattern of preferred biotech buys in recent years: companies that make medicines for cancer and rare diseases.
RBC Capital Markets surveyed investors in December. Their top takeout picks: Clovis (cancer), Sage (neuroscience), Puma Biotechnology (cancer), Bluebird (rare diseases and cancer), and AveXis (rare diseases).